Kristi Kuhn, MD, PhD
In this video, Kristi Kuhn, MD, PhD, associate professor of rheumatology at University of Colorado Anschutz Medical Campus, discusses:
- introducing treatment options, like IL-17 inhibitors or JAK inhibitors, to patients;
- recent advances in biologics for nr-AxSpa, including certolizumab pegol (Cimzia, UCB), secukinumab (Cosentyx, Novartis) and ixekizumab (Taltz, Eli Lilly);
- supplementing treatment with physical therapy and moderate exercise to improve range of motion and reduce pain;
- a “critical limitation in knowledge:” understanding the length of nr-axSpA treatment if few patients will progress;
- a message to physicians to explore beyond an X-ray and diagnose with an MRI; and
- why clinical tests like HLA-B27 and X-rays should not be used to diagnose nr-AxSpa.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.